Skip to main content
OpenTrials
Completed

NCT Number: NCT07070856

Trial of Rice-Based F-75 in Severe Malnutrition & Persistent Diarrhea in Children (SAM-RICE Study)

The goal of this study is to find out if a rice-based version of the F-75 therapeutic food helps children with severe acute malnutrition (SAM) and persistent diarrhea recover better than the standard commercial F-75.

The main questions it aims to answer are:

1. Does rice-based F-75 reduce the duration of diarrhea and improve nutritional recovery in children with SAM? 2. Is rice-based F-75 as safe and well-tolerated as the standard WHO F-75?

Researchers will compare two groups:

One group will receive the new rice-based F-75. The other group will receive the standard F-75.

Participants will:

1. Be children aged 6 to 59 months admitted with SAM and persistent diarrhea 2. Be randomly assigned to one of the two feeding groups 3. Stay in a hospital ward for monitoring during the stabilization phase

Be assessed daily for:

Stool frequency Weight changes Appetite Medical problems or side effects

This study will help determine whether the rice-based F-75 is a better option for malnourished children with diarrhea.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Persistent diarrhea in children with severe acute malnutrition (SAM) poses a significant clinical challenge, particularly during the stabilization phase. Standard therapeutic protocols include the use of F-75-a milk-based formula designed to meet the reduced metabolic demands of severely malnourished children. However, lactose content in milk-based F-75 may exacerbate intestinal symptoms in children with secondary lactase deficiency, commonly observed in cases of persistent diarrhea.

Rice-based therapeutic formulations have emerged as promising alternatives, potentially offering superior gastrointestinal tolerance, improved nutrient absorption, and reduced osmolarity compared to conventional milk-based F-75. Rice is hypoallergenic, low in anti-nutritional factors, and contains resistant starches that may support gut integrity and microbial balance during intestinal recovery.

Introducing rice-based F-75 may address dietary intolerance in children with diarrhea-induced lactase deficiency, particularly in low-resource settings where commercial lactose-free preparations are unavailable or unaffordable. This trial seeks to assess whether therapeutic feeding with rice-based F-75 leads to faster stabilization without compromising metabolic safety or nutritional adequacy.Participants are randomized into intervention and control arms during hospitalization, receiving either rice-based or conventional F-75 during the stabilization phase. Transition to F-100 occurs per clinical criteria once acute symptoms resolve.

Clinical monitoring includes:

  • Gastrointestinal Tolerance: Stool frequency, consistency, abdominal distension, emesis, and need for additional rehydration.
  • Metabolic Safety: Serum sodium, potassium, bicarbonate, and creatinine levels evaluated at baseline and mid-stabilization.
  • Nutritional Stabilization: Daily weight, mid-upper arm circumference (MUAC), and feeding tolerance.
  • Adverse Events Surveillance: Identification of allergic responses, metabolic complications, or mortality.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All the children admitted to the hospital with complaints of persistent diarrhea
  • secondary lactose

Exclusion criteria

  • All the children with primary lactose intolerance
  • Those parents /guardians refused permission to participate in the study.
  • Critically ill child admitted to ICUs and emergency department.
  • Patients started therapeutic feeding prior to recruitment in study .

Treatment and study plan

WHO-recommended standard therapeutic milk used for stabilization phase in SAM)

Dietary Supplement

F75 GIVEN INITIALLY 2HOURLY,130 ml per kg than 3 and 4hourly maximum takes 5 to 7 days.

Other names: Stabalization phase feed

HO-recommended Rice based therapeutic milk used for stabilization phase in SAM)

Dietary Supplement

Rice based F75 GIVEN INITIALLY 2HOURLY,130 ml per kg than 3 and 4hourly maximum takes 5 to 7 days.

Primary outcomes

  1. stool frequency

    Time frame: day 1 to day 7 of starting therapeutic feed

    episodes of loose stools per day

Other outcomes

  1. hydration status

    Time frame: day 1 to day 7 of treatment

    IMNCI Protocol

  2. Re feeding syndrome

    Time frame: Day 1 to day 7 of treatment with therapeutic feed

    monitoring of vitals,edema,heart failure,electrolytes imbalance,convulsions

  3. Electrolytes monitoring

    Time frame: Time Frame: Baseline and Day 4

    • Serum Sodium and potassium Unit of Measure: mmol/L

Sponsors and collaborators

Lead sponsor

Children's Hospital and Institute of Child Health, Multan

Other Gov

Registry information

Official study title

Efficacy and Safety of Therapeutic Rice Based F75 In Severely Acute Malnourished Children With Persistent Diarrhea.;A Randomized Control Trial.

Acronym: SAM-RICE

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jul 17, 2025
Registry last updated
Aug 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.